Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTAFR | P25105 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2377074 | 0.95 | PIK3CA (0.50) | PIK3CAPIK3R1PIK3CB | |
| SCHEMBL2378311 | 0.94 | PIK3CA (0.43) | PIK3CAPIK3R1KDM4EPTAFRPIK3CD | |
| SCHEMBL2376863 | 0.94 | PIK3CA (0.43) | PIK3CAPIK3R1KDM4EPTAFRPIK3CD | |
| SCHEMBL2378152 | 0.92 | PIK3CA (0.48) | PIK3CAPIK3R1KDM4E | |
| SCHEMBL2377984 | 0.91 | PIK3CA (0.49) | PIK3CAPIK3R1NAMPTPIK3CB | |
| SCHEMBL2376855 | 0.89 | PIK3CA (0.51) | PIK3CAPIK3R1PIK3CB | |
| SCHEMBL2379013 | 0.89 | PIK3CA (0.52) | PIK3CAPIK3R1PIK3CB | |
| SCHEMBL2379503 | 0.89 | MAPT (0.44) | PIK3CAPIK3R1 | |
| SCHEMBL2377143 | 0.89 | MAPT (0.44) | PIK3CAPIK3R1 | |
| SCHEMBL2378623 | 0.88 | PIK3CA (0.58) | PIK3CAPIK3R1KDM4EPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | PIK3CA 1/4885PIK3R1 5/4885KDM4E 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.